Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $20.00 price target on the stock.

Checkpoint Therapeutics Trading Down 9.3 %

CKPT opened at $3.43 on Thursday. Checkpoint Therapeutics has a 1-year low of $1.36 and a 1-year high of $3.97. The firm’s 50 day simple moving average is $2.82 and its two-hundred day simple moving average is $2.35. The company has a market capitalization of $154.42 million, a PE ratio of -1.86 and a beta of 1.23.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Equities analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in Checkpoint Therapeutics during the second quarter valued at about $34,000. Gladstone Institutional Advisory LLC lifted its holdings in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 20,500 shares in the last quarter. Magnus Financial Group LLC grew its holdings in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 4,000 shares in the last quarter. 180 Wealth Advisors LLC bought a new stake in shares of Checkpoint Therapeutics during the second quarter valued at approximately $96,000. Finally, Choreo LLC lifted its holdings in shares of Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after buying an additional 7,080 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.